CARDIO DIAGNOSTICS HOLDINGS (CDIO)
US14159C1036 - Common Stock
We assign a fundamental rating of 4 out of 10 to CDIO. CDIO was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CDIO as it has an excellent financial health rating, but there are worries on the profitability. CDIO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CDIO has reported negative net income.
CDIO had a negative operating cash flow in the past year.
1.2 Ratios
Looking at the Return On Assets, with a value of -184.16%, CDIO is doing worse than 89.15% of the companies in the same industry.
CDIO has a worse Return On Equity (-223.89%) than 69.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -184.16% | ||
| ROE | -223.89% | ||
| ROIC | N/A |
ROA(3y)-106.21%
ROA(5y)N/A
ROE(3y)-149.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDIO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CDIO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 17.53 indicates that CDIO is not in any danger for bankruptcy at the moment.
CDIO has a Altman-Z score of 17.53. This is amongst the best in the industry. CDIO outperforms 91.28% of its industry peers.
There is no outstanding debt for CDIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.53 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
CDIO has a Current Ratio of 8.51. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a Current ratio of 8.51. This is in the better half of the industry: CDIO outperforms 74.91% of its industry peers.
A Quick Ratio of 8.51 indicates that CDIO has no problem at all paying its short term obligations.
The Quick ratio of CDIO (8.51) is better than 75.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.51 | ||
| Quick Ratio | 8.51 |
3. Growth
3.1 Past
CDIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.33%, which is quite impressive.
The Revenue has grown by 256.90% in the past year. This is a very strong growth!
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)256.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.4%
3.2 Future
CDIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.03% yearly.
The Revenue is expected to grow by 467.90% on average over the next years. This is a very strong growth
EPS Next Y29.68%
EPS Next 2Y27.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year167.4%
Revenue Next 2Y96.12%
Revenue Next 3Y467.9%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CDIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CDIO's earnings are expected to grow with 27.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.03%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CDIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARDIO DIAGNOSTICS HOLDINGS
NASDAQ:CDIO (12/20/2024, 8:00:41 PM)
After market: 0.98 +0.01 (+0.64%)0.9738
-0.05 (-4.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.92%
Inst Owner Change-7.97%
Ins Owners7.85%
Ins Owner Change19.47%
Market Cap39.38M
Analysts82.5
Price Target2.04 (109.49%)
Short Float %4.27%
Short Ratio0.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.85%
Min EPS beat(2)41.18%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)17.46%
Min EPS beat(4)-117.86%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)6.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-93.5%
Min Revenue beat(2)-93.86%
Max Revenue beat(2)-93.14%
Revenue beat(4)0
Avg Revenue beat(4)-88.42%
Min Revenue beat(4)-97.92%
Max Revenue beat(4)-68.76%
Revenue beat(8)0
Avg Revenue beat(8)-92.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.5%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-38.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1103.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.68 | ||
| P/tB | 13.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.09
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -184.16% | ||
| ROE | -223.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-106.21%
ROA(5y)N/A
ROE(3y)-149.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 360.37% | ||
| Cap/Sales | 2560.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.51 | ||
| Quick Ratio | 8.51 | ||
| Altman-Z | 17.53 |
F-Score5
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)553.87%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y29.68%
EPS Next 2Y27.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)256.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-34.4%
Revenue Next Year167.4%
Revenue Next 2Y96.12%
Revenue Next 3Y467.9%
Revenue Next 5YN/A
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-169.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.23%
OCF growth 3YN/A
OCF growth 5YN/A